首页> 外文会议>World biomaterials congress >Cardiac derived ECM enhances cardiogenic properties of Human Cardiac Progenitor Cells
【24h】

Cardiac derived ECM enhances cardiogenic properties of Human Cardiac Progenitor Cells

机译:心脏衍生的ECM增强人类心脏祖细胞的心源性

获取原文

摘要

Introduction: During the last few years, cardiac tissue engineering has emerged as a new therapeutic approach for the regeneration of the infarcted heart. Different factors can influence the success of a tissue engineering application, the most important of which are the choice of cells and matrix. The ideal matrix should promote cell engraftment, survival and differentiation of the transplanted cells as well as mimic the properties of the endogenous cardiac ECM. A porcine derived myocardial matrix hydrogel has been shown to improve cardiac function upon injection into an infarcted heart and to promote cardiogenesis in murine cardiac progenitor cells (mCPCs). However, its effect on clinically applicable human CPCs (hCPCs) still needs to be addressed. Materials, Methods and Results: In this study, we investigated the in vitro influence of the myocardial matrix hydrogel on the cardiogenic phenotype of Sca-1-like human derived CPCs. Human fetal and adult CPCs (hfCPCs and haCPCs) were isolated from heart biopsies and encapsulated in the myocardial matrix and compared to collagen type Ⅰ hydrogels. RT-PCR analysis of encapsulated hfCPCs displayed a significant increase in the cardiac transcription marker Gata-4 as well as in the sarcomeric protein MLC2v and the vascular marker VEGF receptor 2 (VEGF-R2) after 4 days in culture (n=6; p<0.05). Similarly increased levels were observed for early cardiac transcription factors Nkx2.5 and mef-2c as well as vascular markers VEGF-R2 and CD31 when haCPCs were cultured in the matrix compared to collagen (n=5; p<0.05). Cell viability was sustained in both hydrogels up to 1 week in culture, as showed by a cell viability assay. Hematoxylin and Eosin staining showed that the cells remain homogenously dispersed in the hydrogels, with increasing nuclear densities upon culturing. Interestingly, the myocardial matrix cultured human fetal and adult CPCs showed a significant increase in the proliferation marker Ki67 after 4 days in culture when compared to collagen group (n=6 and n=4 respectively; p<0.05). Cellular protein expression of Nkx2.5 and Tnl was also confirmed by immunofluorescence at day 4 and 7. Finally, to evaluate if the matrix is able to preserve CPCs viability, encapsulated CPCs were treated with 500 μM (hfCPCs) or 750 μM (haCPCs) H_2O_2 for 16 hours. Evaluation via Alamar blue assay showed an improved survival of encapsulated cells in the myocardial matrix when compared to the collagen matrix (n=9 and n=8 respectively; p<0.05). Conclusion: In summary, we showed that the myocardial matrix hydrogel is advantageous for hCPCs culture and encapsulation, enhancing CPCs proliferation, survival and cardiogenic potential compared to collagen. This work demonstrates the potential of the myocardial matrix as an in vitro platform and warrants its further investigation for cell transplantation in the diseased myocardium.
机译:简介:在过去的几年中,心脏组织工程学已经成为一种用于梗塞性心脏再生的新治疗方法。不同的因素会影响组织工程应用的成功,其中最重要的是细胞和基质的选择。理想的基质应促进细胞移植,移植细胞的存活和分化以及模拟内源性心脏ECM的特性。猪源性心肌基质水凝胶已被证明可改善心肌梗塞后心脏的功能,并促进小鼠心脏祖细胞(mCPC)的心脏发生。但是,其对临床适用的人类每次点击费用(hCPC)的影响仍然需要解决。材料,方法和结果:在这项研究中,我们研究了心肌基质水凝胶对Sca-1样人源CPC的心源表型的体外影响。从心脏活检组织中分离出人类胎儿和成人CPC(hfCPC和haCPC),并将其封装在心肌基质中,并与Ⅰ型胶原水凝胶进行比较。封装的hfCPC的RT-PCR分析显示,培养4天后,心脏转录标记物Gata-4以及肌节蛋白MLC2v和血管标记物VEGF受体2(VEGF-R2)显着增加(n = 6; p <0.05)。当在基质中培养haCPC时,与胶原相比,早期心脏转录因子Nkx2.5和mef-2c以及血管标志物VEGF-R2和CD31的水平也有所增加(n = 5; p <0.05)。如细胞生存力测定所示,两种水凝胶中的细胞生存能力均维持至培养1周。苏木精和曙红染色显示细胞在水凝胶中保持均匀分散,培养后细胞核密度增加。有趣的是,与胶原蛋白组相比,培养4天的人胎和成人CPC心肌基质显示出增殖标志物Ki67的显着增加(分别为n = 6和n = 4; p <0.05)。 Nkx2.5和Tnl的细胞蛋白表达也在第4天和第7天通过免疫荧光确认。最后,为了评估基质是否能够保留CPC的生存能力,用500μM(hfCPC)或750μM(haCPC)处理封装的CPC H_2O_2持续16小时。与胶原蛋白基质相比,通过Alamar蓝分析的评估显示心肌基质中包封细胞的存活率有所改善(分别为n = 9和n = 8; p <0.05)。结论:总之,我们表明,与胶原蛋白相比,心肌基质水凝胶有利于hCPCs的培养和封装,增强CPC的增殖,存活和心源性潜力。这项工作证明了心肌基质作为体外平台的潜力,并保证了其对患病心肌细胞移植的进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号